UroGen Pharma to Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 10, 2022

Rhea-AI Summary

UroGen Pharma Ltd. (Nasdaq: URGN) will announce its fourth quarter and full-year 2021 financial results on March 10, 2022, prior to market open. Following the announcement, a live audio webcast and conference call will be held at 10:00 AM ET. UroGen focuses on innovative treatments for urothelial and specialty cancers, with products like Jelmyto and the investigational UGN-102. These therapies utilize RTGel™, a proprietary hydrogel technology intended to enhance drug delivery in the urinary tract.

Positive

• UroGen's RTGel™ technology could enhance therapeutic profiles of existing drugs.
• The upcoming financial results may provide insight into the company's growth and performance.

Negative

• None.

Conference Call and Webcast Scheduled for Thursday, March 10, 2022, at 10:00 AM ET

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2021 financial results on Thursday, March 10, 2022, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.

Audio Webcast
The webcast will be made available on the Investors section of the Company’s website at http://investors.urogen.com. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.

Dial-In Information
Live (U.S. / Canada): (855) 765-5685
Live (International): (615) 247-5916
Confirmation number: 7897224

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product Jelmyto (mitomycin) for pyelocalyceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220304005511/en/

INVESTORS:

Vincent Perrone

vincent.perrone@urogen.com

609-460-3588 ext. 1093

MEDIA:

Cindy Romano

Director, Corporate Communications

cindy.romano@urogen.com

609-460-3583 ext. 1083

Source: UroGen Pharma Ltd.

FAQ

When will UroGen Pharma report its fourth quarter and full-year 2021 financial results?

UroGen Pharma will report its financial results on March 10, 2022, prior to the stock market opening.

What is UroGen Pharma's stock symbol?

UroGen Pharma's stock symbol is URGN.

What products does UroGen Pharma focus on?

UroGen Pharma develops treatments for urothelial and specialty cancers, including Jelmyto and UGN-102.

What is the purpose of the March 10 conference call?

The conference call will discuss UroGen's financial results and company developments.